Research shows Hispanics living with HIV at high risk of developing diabetes and obesity

September 6, 2016

Patients receiving life-saving, anti-retroviral treatment for HIV are living longer and healthier lives. But there is a downside: As they age, individuals living with HIV are at greater risk of developing heart disease and other chronic health conditions due to HIV-associated inflammation as well as the medications that control the virus. This can pose special problems for patients who live in lower- and middle-income Latin American countries, such as Mexico and the Dominican Republic, where resources for primary care are limited, according to a new study in the August edition of the journal PLOS ONE.




MedPage Today: Triple Combo Tx Durable for T2D

September 1, 2016

Starting newly-diagnosed diabetes patients on the triple combination of metformin/pioglitazone/exenatide upfront provided better glucose control with less hypoglycemia than a standard sequential regimen, 3-year follow-up from the EDICT trial showed. Read the full story at MedPage Today





Stock Transcript: VeroScience supports DeFronzo’s research

May 26, 2016

VeroScience LLC, is pleased to announce that independent research conducted by Dr. Ralph DeFronzo and his team at UT Health Science Center at San Antonio (“Health Science Center“) has continued to delineate metabolic targets of VeroScience’s Cycloset® in reducing hyperglycemia in type 2 diabetes mellitus (T2DM) patients. The study has also identified positive influences of the […]